康方生物(09926.HK) 公布,自研的全球首创双特异性抗体“依达方”(依沃西,PD-1/VEGF)联合化疗方案,对比度伐利尤(PD-L1)联合化疗方案一线治疗晚期胆道癌的三期临床研究,经独立数据监察委员会评估的预先设定期中分析显示,该研究已达到总生存期(OS)主要研究终点,取得具有统计学显著和重大临床获益的阳性结果。该研究同时达到无进展生存期(PFS)与客观缓解率(ORR)的所有关键次要终点。...
Source Link康方生物(09926.HK) 公布,自研的全球首创双特异性抗体“依达方”(依沃西,PD-1/VEGF)联合化疗方案,对比度伐利尤(PD-L1)联合化疗方案一线治疗晚期胆道癌的三期临床研究,经独立数据监察委员会评估的预先设定期中分析显示,该研究已达到总生存期(OS)主要研究终点,取得具有统计学显著和重大临床获益的阳性结果。该研究同时达到无进展生存期(PFS)与客观缓解率(ORR)的所有关键次要终点。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.